Laurent C.A. Melchior Tellier returns as CEO of Genomic Prediction

Since 2017, Laurent C.A. Melchior Tellier has served on Genomic Prediction's board as a member, providing scientific guidance alongside co founder Stephen Hsu. Their core technology, used in LifeView tests was developed and published through their research collaboration before the company was founded.

Laurent C.A. Melchior Tellier is an experienced scientist and entrepreneur who has guided Genomic Prediction since the beginning. He co-founded the company in 2017 and first served as CEO and CTO, before focusing on building the Genomic Prediction Clinical Laboratory, helping turn research into real healthcare solutions.

Read More:ActionAI raises $10M seed funding to improve AI trust

"This is an exciting time for Genomic Prediction, as we again continue to advance the state of the art in genetic testing and genomics technology. "I am excited to advance further our LifeView platform and the PGT-P technology we developed and named, which is now widely used," Tellier says. "Genomic Prediction is proud to help IVF patients partner with their physicians to make better-informed decisions and exert reproductive autonomy. There is so much potential yet to be tapped in the field of preimplantation genetic testing, and I am excited to take the lead as we move forward toward unprecedented innovation."

"Under Laurent Tellier's steady leadership, Genomic Prediction has advanced the application of genomic technologies and democratized access to genomic data to support effective decision-making in IVF," says Santiago Munné, Ph.D., Genomic Prediction's chief scientific officer and a highly regarded pioneer in preimplantation genetic testing. "Laurent's guidance over the past nine years has also played a key role in developing and maintaining the company's extremely high standards for scientific rigor, transparency, and patient care."

About Genomic Prediction

Founded in 2017 by Laurent C.A. Melchior Tellier, Genomic Prediction is a leader in advanced embryo screening. Its LifeView platform uses modern technology to analyze embryos for genetic traits. The company’s research began years earlier, with key partnerships starting in 2015 and a decade of work in embryology, genomics, and genetic analysis leading to its advanced testing methods. Today, its products improve on existing approaches to deliver more accurate genetic insights.

Read More:PickleRage names Rich DeStasio as CEO to lead growth